University of Utah Cell Therapy and Regenerative Medicine Facility, Salt Lake City, Utah, USA.
Cytotherapy. 2013 Dec;15(12):1458-68. doi: 10.1016/j.jcyt.2013.06.014.
Fetal bovine serum (FBS) is commonly used as a serum supplement for culturing human mesenchymal stromal cells (hMSCs). However, human cells grown in FBS, especially for extended periods, risk potential exposure to bovine immunogenic proteins and infectious agents. To address this issue, we investigated the ability of a novel human platelet serum supplement to substitute for FBS in hMSC cultures.
Platelet lysate-serum (PL-serum) was converted from platelet lysate-plasma (PL-plasma) that was manufactured from pooled platelet-rich plasma (PRP) apheresis units. Growth factor levels and the number of residual intact platelets in PL-serum and PL-plasma were compared with enzyme-linked immunosorbent assays and flow cytometry, respectively. Proliferation responses of hMSCs cultured in PL-serum, PL-plasma, or FBS were assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, the immunophenotype of harvested hMSCs was evaluated by flow cytometry and tri-lineage differentiation potential was evaluated by assessing adipogenic, osteogenic and chondrogenic development.
Selected growth factor levels in PL-serum were not significantly different from PL-plasma (P > 0.05). hMSC cultures supplemented with PL-serum had comparable growth kinetics to PL-plasma, and hMSC yields were consistently greater than with FBS. hMSCs harvested from cultures supplemented with PL-serum, PL-plasma or FBS had similar cell surface phenotypes and maintained tri-lineage differentiation potential.
PL-serum, similar to PL-plasma, can substitute for FBS in hMSC cultures. Use of PL-serum, in contrast to PL-plasma, has an added advantage of not requiring addition of a xenogeneic source of heparin, providing a completely xeno-free culture medium.
胎牛血清(FBS)通常被用作培养人间质基质细胞(hMSC)的血清补充物。然而,在 FBS 中生长的人类细胞,特别是在延长的时间内,存在潜在暴露于牛免疫原性蛋白和感染性因子的风险。为了解决这个问题,我们研究了一种新型人血小板血清补充物替代 hMSC 培养中 FBS 的能力。
血小板裂解物-血清(PL-血清)由从血小板富血浆(PRP)离心单位制备的血小板裂解物-血浆(PL-血浆)转化而来。通过酶联免疫吸附试验和流式细胞术分别比较 PL-血清和 PL-血浆中的生长因子水平和残留完整血小板数量。通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)测定法评估 hMSC 在 PL-血清、PL-血浆或 FBS 中培养的增殖反应,通过流式细胞术评估收获的 hMSC 的免疫表型,并通过评估脂肪形成、成骨和软骨形成来评估三系分化潜能。
PL-血清中的选定生长因子水平与 PL-血浆无显著差异(P > 0.05)。补充 PL-血清的 hMSC 培养具有与 PL-血浆相当的生长动力学,并且 hMSC 产量始终大于 FBS。从补充 PL-血清、PL-血浆或 FBS 的培养物中收获的 hMSCs 具有相似的细胞表面表型,并保持三系分化潜能。
PL-血清与 PL-血浆相似,可以替代 hMSC 培养中的 FBS。与 PL-血浆相比,使用 PL-血清具有额外的优势,即不需要添加异种来源的肝素,提供完全无异种的培养基。